MiraLAX Joins Claritin As S-P OTC Sales Driver In Second Quarter
This article was originally published in The Tan Sheet
Executive Summary
A 23 percent increase in Claritin sales was a key driver in the performance of Schering-Plough's Consumer Health Care division during its fiscal 2007 second quarter, the firm said July 23
You may also be interested in...
S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal
Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns
The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products